FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:877-879 September 16, 1993 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The thalassemias are common single-gene disorders and pose an important public health problem in many countries. In recent years there has been great progress in determining the molecular pathology of the different forms of thalassemia and in understanding the basis for their remarkable clinical heterogeneity¹. This knowledge has been applied in the clinic for the detection of carriers and the prenatal diagnosis of the more severe forms, particularly beta-thalassemia. The result has been a major reduction in the number of new cases of thalassemia, notably in Greece, Italy, and the Mediterranean islands².

Despite these successes, many children continue . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Mauer, M., Zinman, B., Gardiner, R., Drummond, K. N, Suissa, S., Donnelly, S. M, Strand, T. D, Kramer, M. S, Klein, R., Sinaiko, A. R (2002). ACE-I and ARBs in early diabetic nephropathy. Journal of Renin-Angiotensin-Aldosterone System 3: 262-269 [Abstract]  
• Bergeron, R. J., Wiegand, J., Brittenham, G. M. (2002). HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 99: 3019-3026 [Abstract] [Full Text]  
• Bergeron, R. J., Wiegand, J., Brittenham, G. M. (1999). HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 93: 370-375 [Abstract] [Full Text]  
• Bergeron, R. J., Wiegand, J., Brittenham, G. M. (1998). HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 91: 1446-1452 [Abstract] [Full Text]  
• Soutar, R. L, King, D. J (1995). Fortnightly Review: Bone marrow transplantation. BMJ 310: 31-36 [Abstract] [Full Text]